85 results about "Pyridoxamine" patented technology

The present invention provides a composition comprising an effective amount of benfotiamine and an effective amount of pyridoxamine in a suitable vehicle for topical application. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles, loss of elasticity, and hyperpigmentation caused by chronoaging and/or photoaging of skin, by inhibiting particularly skin damage resulting from reactive carbonyl species (RCS), glycation of skin proteins, formation of advanced glycation endproducts (AGEs) and formation of advanced lipoxidation endproducts (ALEs).

Method of limiting development of acute kidney injury (AKI) and treating AKI using pyridoxamine are described, together with methods for monitoring efficacy of pyridoxamine therapy.

The present invention provides a method of administering vitamin B6 related compounds for treatment of hypertriglyceridemia. Vitamin B6 related compounds include pyridoxal, pyridoxal-5′-phosphate, pyridoxamine, a 3-acylated analogue of pyridoxal, a 3-acylated analogue of pyridoxal-4,5-aminal, and mixtures thereof. Embodiments of the present invention also comprise co-administering a lipid lowering agent, such as a nicotinic acid, a fibrate, a HMG CoA reductase inhibitor, a cholesteryl ester transfer protein inhibitor, and combinations thereof.

A method of treating angina in a mammal includes administering pyridoxal-5′-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.

A method of treating a cerebrovascular disease, particularly stroke, is described. A method of treating a cerebrovascular disease includes administering pyridoxal-5'-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyriodoxal-4,5-animal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.

A method of modulating cell death includes administering pyridoxal-5′phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.

Methods for treating cardiovascular and related diseases such as ischemia, ischemia reperfusion injuries, and myocardial ischemia, are described. The methods are directed to concurrently administering a compound such as pyridoxal-5′-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound.

Methods for treating cardiovascular and related diseases such congestive heart failure are described. The methods are directed to concurrently administering a compound such as pyridoxal-5′-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound.

The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.

A method of treating and/or preventing oxidative damage, comprising administering an effective IsoK/NeuroK adduct formation suppressing amount of a phenolic amine compound and/or pyridoxamine or pyridoxamine analog, including embodiments where the phenolic compound is at least one of a pyridoxamine, salicylamine, tyrosine compound or an analog thereof.

The invention includes a method of treating atrial fibrillation in a mammal that includes administering a therapeutically effective amount of at least one therapeutic compound Compounds suitable for use in the methods of the invention include pyridoxal-5′-phosphate, pyridoxic acid, pyridoxamine, pyridoxal, 3-acylated pyridoxal analogues, pharmaceutically acceptable acid addition salts thereof, and mixtures thereof.

The present invention relates to a beverage, in particular, it relates to a health-care beverage capable of protecting and raising visual acuity. The raw material composition of said health-care beverage includes the following several components: white granulated sugar, peach juice, carrot juice, tomato pulp, citric acid, sorbic acid, xanthophylls, vitamin B1, vitamin B2, vitamin C, beta-carrotene, pyridoxamine, carboxymethyl cellulose, pectin and pure water. Said invention also provides its preparation method and concrete operation steps.

The invention discloses a medicine for treating cardiovascular disease. The medicine comprises the following components: 25-40 parts of herbal powder, 5-10 parts of ginkgo biloba extract, 5-10 parts of erigeron breviscapus powder, 0.2-0.5 part of a nitric oxide production accelerant, and 0.5-1 part of a platelet aggregation reducing agent. The raw materials are uniformly mixed according to the proportion, so as to obtain the medicine. The nitric oxide production accelerant is a mixture of arginine, citrulline and folic acid; the platelet aggregation reducing agent is any one of pyridoxine, pyridoxal and pyridoxamine; the herbal powder comprises the following components: 15-20 parts of radix puerariae, 15-20 parts of astragalus membranaceus, 10-15 parts of cyperus rotundus, 5-10 parts of radix curcumae, 5-10 parts of trichosanthes kirilowii, 3-5 parts of pinellia ternata, 3-5 parts of scutellaria baicalensis, 1-3 parts of schisandra chinensis, 2-4 parts of glossy privet fruit, 3-6 parts of fruit of Chinese wolfberry, 1-3 parts of semen cuscutae, 2-5 parts of herba epimedii and 1-3 parts of fructus psoraleae. The medicine provided by the invention has quick curative effect on cardiovascular disease, is short in treatment course, has good curative effect on the cardiovascular disease, and has a certain protection function on spleen, stomach and liver.

The invention relates to a novel chiral open-chain pyridoxamine catalyst and a synthesis method and application thereof. The structural general formula of the pyridoxamine catalyst is shown in the specification, wherein R1, R2, R3 and R4 are one of hydrogen, C1-24 alkyl, C1-24 alkyl containing substituent groups, substances shown in the specification and halogen, the substituent groups on C1-24 alkyl are a substance shown in the specification or a substance shown in the specification or a substance shown in the specification or O-Rw or S-Rw' or halogen, and Rx, Rx', Ry, Ry', Ry'', Rz, Rz', Rw and Rw' are one of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiary butyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, (1-phenyl)ethyl, 1-naphthyl, 2-naphthyl and halogen. Compared with the prior art, the pyridoxamine catalyst can achieve rapid and efficient synthesis of chiral amino acid, the preparation raw materials are easy to obtain, reaction conditions are mild, cost is low, and when the novel chiral open-chain pyridoxamine catalyst is used for a transamination reaction, the conditions are mild, and the reaction is stable.

A method of treating a cerebrovascular disease, particularly stroke, is described. A method of treating a cerebrovascular disease includes administering pyridoxal-5'-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.

The invention relates to a feed additive for enhancing immunity of yellow catfish, which is prepared from, by weight, 5-8 parts of L-lysine, 1-3 parts of magnesium acetate, 1-3 parts of organic selenium, 1-3 parts of trehalose, 2-5 parts of taurine, 5-8 parts of calcium pantothenate, 8-12 parts of creatine monohydrate, 5-8 parts of L-citrulline, 3-6 parts of sodium propionate, 2-5 parts of zinc gluconate, 5-8 parts of calcium hydrophosphate, 3-6 parts of calcium glycinate, 3-6 parts of pyridoxamine, 2-5 parts of folic acid, 2-5 parts of choline chloride, 5-8 parts of betaine, 2-4 parts of dimethyl-beta-propiothetin, 2-5 parts of sodium chloride, 2-5 parts of inositol, 1-3 parts of vitamin A, 1-3 parts of vitamin B, 5-8 parts of vitamin C, and 2-5 parts of vitamin E. The feed additive can effectively improve the diseases prevention and resistance effect of the yellow catfish and can enhance immunity.

The invention relates to a preparation method of a piglet feed. The piglet feed is prepared from, by weight, 350-370 parts of corn protein powder, 120-140 parts of rice bran, 220-240 parts of fermented soybean meal, 120-140 parts of sweet potato bran, 60-80 parts of whey powder, 10-20 parts of zeolite powder, 5-10 parts of betaine, 5-10 parts of garlic powder, 2-5 parts of nicotinic acid, 8-12 parts of citric acid, 2-5 parts of vitamin C, 2-5 parts of methionine, 3-5 parts of calcium phosphate, 3-8 parts of sodium diacetate, 10-15 parts of pyridoxamine, 3-5 parts of sodium chloride, 5-10 parts of calcium glycinate, 5-10 parts of taurine, 3-8 parts of L-citrulline, 3-8 parts of L-phenylalanine, and 2-5 parts of zinc lactate. The feed has the advantages of satisfactory improvement of the nutrition balance of piglets, facilitation of enhancement of the immunity, and promotion of the growth.

The present invention relates to treatments and therapies for anemia conditions and diseases of the blood, and more particular is a therapy for the acute and chronic treatment of sickle cell diseases and thalassemia by administration of pyridoxamine, or a pharmaceutically acceptable salt thereof, optionally in combination with an additional bioactive agent.